BOTH aspirin and sulfinpyrazone have been utilized as antithrombotic agents and have been evaluated in recent clinical trials for the prevention of stroke {Canadian Co-operation Stroke Study Group, 1978) and myocardial infarction (Anturane Re infarction Trial Research Group, 1980) . The mechanism of action whereby these two drugs exert their antithrombotic activity is incompletely under-stood. It is known that both aspirin and sulfinpyrazone inhibit platelet cyclooxygenase (Ali, and McDonald, 1977; Moncada et al., 1979) the former by irreversible acetylation and the latter in a reversible manner. We have now compared the ability of these two drugs to preserve circulating platelets during extracorporeal perfusion. We have previously developed a standardized extracorporeal perfusion protocol to evaluate means of preserving circulating platelets. The perfusion is conducted in sheep and the extracorporeal circuit includes a membrane oxygenator. Following insertion of the membrane oxygenator into the perfusion circuit, a marked, reversible loss of circulating platelets and white cells occurs. At the same time a reversible rise in the pulmonary vascular resistance occurs. We previously demonstrated that pretreatment of the animal with sulfinpyrazone significantly preserves platelets and virtually eliminates the temporary increase in pulmonary vascular resistance . The pulmonary vascular response appears to be triggered by an activation of the plasma complement system (Lindsay et al., 1976) which, in turn, is associated with generation of prostaglandins and thromboxanes (Cooper et al., 1980) .
The current experiments were designed to determine whether aspirin, like sulfinpyrazone, would inhibit the pulmonary vascular response during extracorporeal perfusion in sheep, and if so, whether the two drugs would equally preserve circulating platelets.
Methods
Sheep weighing 30-40 kg were cannulated for veno-venous extracorporeal perfusion as previously described . In summary, under ket&mine sedation, cannulas were inserted into each common jugular vein for connection to the extracorporeal circuit. A carotid arterial cannula was inserted to monitor systemic arterial pressures. A specially modified Swan-Ganz thermodilution catheter (Edwards Laboratories #78567) having the injection port positioned 15 cm from the tip, was inserted to monitor pulmonary artery and pulmonary wedge pressures and for determination of cardiac output by the thermodilution method. When the animal was fully recovered (116-2 hours), it was attached to the extracorporeal circuit with the membrane oxygenator initially excluded from the circuit for a 2-hour control period. The oxygenator was a 2.5 M 2 spiral coil membrane oxygenator (Sci-Med Inc.). New silicone rubber tubing and polycarbonate tubing connectors were used for each experiment. At the time of oxygenator insertion, perfusion was set at 500 ml/min for the first 15 minutes, and thereafter at 1 liter/min for a total oxygenator perfusion time of 2 hours.
Systemic and pulmonary artery pressures were measured by Statham transducers (P-23-DIA) connected to a Litton multi-channel recorder for continuous display and recording. Cardiac output determinations were made in triplicate utilizing the Edwards Cardiac Output Computer (model #9510). Venous blood samples were drawn prior to perfusion and thereafter at regular intervals for determination of hematocrit, leukocyte, and platelet counts. Hematocrit was measured by the microcentrifuge method and leukocyte and platelet counts were measured with a Coulter Counter (Coulter Electronics, Inc.) as previously described (Osada et al., 1978) . Blood samples were withdrawn from the carotid artery, pulmonary artery, and extracorporeal circuit, proximal and distal to the membrane oxygenator, for determination of the plasma throm-boxane B 2 level. These samples were immediately placed in tubes containing 0.07 ml of 15% EDTA (Vacutainer #6450 MS 3204 QS) and centrifuged at 18,000 RPM at 0 to 4°C. The supernatant then was separated into glass tubes which were frozen and stored at -30°C while awaiting assay by a radioimmuno technique . The membrane oxygenator and perfusion circuit were primed in an identical manner for all experiments, utilizing Ringer's lactate solution containing 10 ml of 7.5% sodium bicarbonate and 4000 units of heparin per liter.
To eliminate trapped bubbles, the priming solution was recirculated through the circuit for 90 minutes prior to its attachment to the animal. Following recirculation, the oxygenator was excluded from the circuit by means of a bypass shunt around it, and the circuit was then attached to the previously inserted jugular cannulae of the sheep.
At the time of cannulation, the animal was given heparin, 1.25 mg/kg, iv. This dose was repeated 30 minutes later. Subsequently, herparin was administered at a rate between 0.5 and 1 mg/kg per hr, the exact dosage depending upon the activated clotting time (ACT) as measured by the Hemochron apparatus (International Technedyne Corporation). Activated clotting time was maintained between 400 and 600 seconds throughout the perfusion.
Three groups of animals were studied: Group 1 (n = 4) received no drug pretreatment and served as controls. Group 2 (n = 5 received aspirin, 50 mg/ kg, iv, over 10 minutes, 1 hour prior to oxygenator insertion.
Group 3 (n = 4) received 1.5 g of sulfinpyrazone. This was administered into the perfusion circuit over 10 minutes, 1 hour before insertion of the oxygenator into the circuit.
The aspirin was obtained from Sigma Chemical Company and was freshly prepared for each experiment. Ten grams of aspirin were slowly added to 80 ml of water with a continuous addition of 25% sodium carbonate solution as a buffer to maintain pH between 6.8 and 7.2. After the aspirin was completely dissolved, this solution was diluted with water to a total of 100 ml (10% solution of ASA). The solution was then frozen at -70°C and thawed immediately prior to use. The pH was rechecked just prior to use. Sulfinpyrazone solution (1600 mg in 15 ml) was obtained in sealed ampules from the Ciba-Geigy Company.
In three of the animals receiving aspirin, venous samples were withdrawn for assay of the plasma aspirin level. Samples were taken each 5 minutes for the first 30 minutes and hourly thereafter for 4 hours. The samples were collected in tubes containing 14 mg of potassium oxylate and 17.5 mg sodium fluoride (Vacutainer #6470 MS 3204 PS). The samples were immediately placed on ice and spun at 18,000 RPM for 10 minutes at 0 to 4°C. The supernatant was separated and quick frozen in a dry ice- Mean pulmonary artery pressure during 2hour baseline perfusion, and following oxygenator insertion. Since cardiac output showed no significant change, the increased pulmonary artery pressure in control animals is entirely due to an increase in pulmonary vascular resistance.
acetone bath. Samples were stored at -70°C for subsequent analysis using high pressure liquid chromatography as previously described . Statistical analysis of data was performed by the use of Students's paired £-test when comparing control and experimental values within each group, whereas the unpaired £-test was used for comparison between different groups.
Results

Pulmonary Vascular Response (see Fig. 1)
The pulmonary artery pressure in group 1 animals rose by 64%, with a peak at 16 minutes. Groups 2 and 3 showed no rise in pulmonary artery pressure. The pressure increase in group 1 animals was highly significant compared with group 2 and group 3 animals (P < 0.01 at 16 minutes). The cardiac output did not change significantly in any of the groups, and thus the increase in the pulmonary artery pressure in group 1 animals is due entirely to an increase in pulmonary vascular resistance.
Platelet Preservation (see Fig. 2 ).
The circulating platelet count (corrected for hematocrit changes due to blood sampling and hemodilution) fell almost identically in groups 1 and 2. The maximum loss occurred approximately 12 minutes after oxygenator insertion with the platelet counts in groups 1 and 2 approximately 40% of the level just prior to oxygenator insertion. In group 3 animals (sulfinpyrazone pretreatment), platelet counts declined by only 23%, which represented a highly significant preservation compared with either group 1 or group 2 (P < 0.01, 12 to 120 minutes, inclusive).
White Blood Cell Count (see Fig. 3)
The total white cell count showed an identical fall in all three groups, with a maximum fall of 75% occurring between 12 and 16 minutes. The rebound of the white cell count occurred more rapidly in group 3 animals than in the other groups (P < 0.05, 30-120 minutes). The platelet count was corrected for changes in hematocrit due to hemodilution and blood sampling. Platelet count is expressed as a percentage of platelet count at the time of oxygenator insertion. Platelet preservation in sulfinpyrazonepretreated animals was highly significant (P < 0.01, 12-120 minutes, inclusive) . 
Loss of Platelets to Oxygenator
The platelet count was determined in samples simultaneously drawn from blood entering and exiting from the oxygenator. Platelet clearance across the oxygenator was determined, and expressed as a percentage of platelets lost from blood traversing the oxgenator:
Platelets In -Platelets Out Platelets In The results are shown in Figure 4 . Group 3 showed a significant reduction in platelet clearance by the oxygenator (P < 0.01 at 8 minutes). There was no significant difference between groups 1 and 2.
The pressure in the perfusion circuit was continuously monitored proximal and distal to the oxygenator to measure changes in resistance to blood flow through the oxygenator. Figure 5 shows the results during the first 15 minutes, during which the blood flow was constant at 500 ml/min. In group 3, there was little change in membrane resistance, whereas groups 1 and 2 showed a steady increase in resistance. This increased resistance presumably reflects platelet deposition on the surface of the membrane.
Thromboxane Synthesis (see Fig. 6 ) Shortly after the onset of perfusion through the oxygenator, group 1 (control) animals showed a definite, though highly variable increase in the plasma thromboxane B2 level. This was not the case for group 2 or group 3. The peak elevation in thromboxane B2 for each group 1 animal occurred at the same time as the peak rise in pulmonary artery pressure.
Aspirin Levels
The aspirin level reached a peak between 145 and 185 jig/ml immediately after administration.
Sixty minutes after administration, at the time of oxygenator insertion, the aspirin level was 6 /ig/ml. The salicylate level rose steadily following aspirin administration, reaching a peak of 55-85 j^g/rnl at 32 minutes, falling slowly over the next 2 hours.
Discussion
Extracorporeal perfusion with both bubble and membrane oxygenators is associated with a decrease in platelet count. With long-term membrane oxygenator perfusion for respiratory support, this thrombocytopenia, coupled with the requirement for systemic anticoagulation contributes to the potential for hemorrhagic complications.
In 1973, Becker demonstrated that the use of dipyridamole, 10 mg/kg, improved platelet preservation during the first hour of cardiopulmonary bypass in pigs (Becker, 1973) . However, the beneficial effects were not apparent after 2 hours of perfusion. Bloom et al., (1974) used a perfusion system somewhat similar to the one we have employed and evaluated platelet preservation during 24 hours of perfusion, utilizing a variety of anti-platelet agents. Resistance to blood flow through oxygenator as determined by measurement of the pressure differential across the membrane oxygenator at constant blood flow (500 ml/min). A steady, equal increase in resistance occurred in groups 1 and 2, but no significant change occurred in group 3 animals, presumably reflecting the decreased platelet adherence to the oxygenator seen in this group of animals.
They studied pretreatment with aspirin (25 mg/kg), flurbioprofen (10 mg/kg) (<f£-2-[2-fluoro-4-biphenylyl] propionic acid), and dipyridamole (2.5-4.0 mg/ kg given in repeated doses). None of these agents demonstrated the ability to preserve platelets in comparison with untreasted animals. Mielke et al., 1973 studied drug influence on platelet loss during extracorporeal perfusion with a bubble oxygenator. Aspirin (65 mg/kg), pluronic-68 (75 mg/kg), sudoxicam (15 mg/kg), and dipyridamole (2 mg/kg) were evaluated in separate experiments. Only dipyridamole was found to improve platelet preservation, though even with this agent more than 50% of circulating platelets were lost in the first hour. More recently, Addonizio et al., (1979) , studying human blood in an in vitro perfusion circuit, demonstrated that platelet loss from fresh heparinzed human blood was not affected by previous ingestion of low dose aspirin by the donors. They did note, however, that perfusion with blood from donors taking aspirin produced no rise in thromboxane B2 levels, whereas perfusion with the blood of normal donors did produced such a rise.
We have previously demonstrated that pretreatment with sulfinpyrazone reproducibly results in significant platelet preservation during both 4-and 24-hour membrane oxygenator perfusions in sheep . We noted as well that sulfinpyrazone pretreatment eliminated the increased pulmonary vascular resistance normally present shortly after the onset of membrane oxygenator perfusion. The mechanism for the rise in pulmonary vascular resistance was not understood at the time, but it was subsequently shown that complement activation, known to occur during extracorporeal perfusion, is associated with the release of vasoactive prostaglandin metabolites. Infusion of autologous complement-activated plasma in sheep was found to produce a rise in plasma thromboxane B2 levels, concomitant with a rise in pulmonary vascular resistance (Cooper et al., 1980) . Our finding that aspirin, as well as sulfinpyrazone, would block this response in sheep, prompted reevaluation of the effect of aspirin during extracorporeal perfusion. The animal perfusion model employed to study platelet loss has been utilized in over 120 sheep perfusions and gives uniform results. Preparation of the aspirin was done in a manner to ensure the absence of hydrolysis to the inactive form, salicylic acid. In addition, aspirin levels in blood were monitored to ensure presence of the active agent. Finally we demonstrated that aspirin, as prepared and administered in these experiments, effectively blocked a generation of thromboxane B2 following the onset of extracorporeal perfusion. The failure of aspirin to preserve platelets in these experiments clearly demonstrates a difference between the mechanism of action of sulfinpyTazone and that of aspirin, at least regarding platelet loss during extracorporeal perfusion. The dose of aspirin used for these experiments (50 mg/kg) was more than sufficient to ensure complete suppression of platelet function. A dose of 1 mg/kg acetylsalicylic acid (ASA) completely suppresses platelet thromboxane formation in rabbits, sheep, and humans. We have demonstrated that a dose of 10 mg/kg in sheep suppresses platelet cyclooxygenase for more than 4 hours, and blocks in vitro platelet aggregation in response to thrombin or arachidonic acid. It appears reasonable, therefore, to conclude that the failure of aspirin to produce the same platelet-sparing effect as sulfmpyrazone was not due to inadequate dosage of aspirin. Sulfinpyrazone clearly appears to reduce platelet adhesion to the membrane surface in a manner independent of platelet thromboxane synthesis. This confirms the findings of Addonizio et al. (1979) . In their model, however, the investigators studied an in vitro extracorporeal circuit, and we have previously documented (unpublished data) that platelet behavior in such a circuit does not reflect platelet kinetics as occur during actual animal perfusion.
The current experiments provide additional evidence for mediation by thromboxane A 2 of the pulmonary hypertension associated with complement activation. In earlier studies, infusion of plasma containing activated complement caused elevated thromboxane levels and elevated pulmonary artery pressures. The two phenomena appeared to be related in time, and both were blocked by sulfinpyrazone and indomethacin pretreatment of the animals. In the present experiments, the animals were subjected to a procedure known to cause complement activation, and the changes in pulmonary vascular resistance and in thromboxane levels were again temporally related. The cyclooxygenase inhibitors ASA and sulfinpyrazone again blocked the synthesis of thromboxanes and the increase in pulmonary artery pressure. Since platelets were preserved only by sulfinpyrazone, it is apparent that pulmonary hypertension is more closely related to thromboxane synthesis than to platelet disappearance.
The relationship, if any, between the leukopenia and the platelet loss in these experiments remains unclear. It now appears (Craddock, 1977b ) that the Csa component of complement is responsible for the leukocytosis occurring following exposure of blood to artifical surfaces. Furthermore, the finding of Craddock et al. (1977a) that complement-activated plasma produces no pulmonary response in sheep rendered acutely neutropenic suggests that the leukocytes are either directly or indirectly involved in the thromboxane production stimulated by activation of the complement system.
In our experiments, the leukopenia produced by oxygenator perfusion was identical in all groups of animals. In these experiments, as in previous ones, the rebound of the white blood cell count does appear to be related to the degree of platelet loss, with lesser platelet loss being associated with more rapid rebound of the peripheral white count. This has been a consistent finding in our experiments and may reflect the formation of leukocyte-platelet aggregates concomitant with the platelet loss.
